Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Shorted Shares Decreased By 1.86%

May 17, 2018 - By Robert Crowder

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Logo

The stock of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) registered a decrease of 1.86% in short interest. BCLI’s total short interest was 1.27M shares in May as published by FINRA. Its down 1.86% from 1.30M shares, reported previously. With 29,600 shares average volume, it will take short sellers 43 days to cover their BCLI’s short positions. The short interest to Brainstorm Cell Therapeutics Inc’s float is 7.84%.

The stock decreased 2.65% or $0.11 during the last trading session, reaching $4.04. About 164,664 shares traded or 146.00% up from the average. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has declined 23.19% since May 17, 2017 and is downtrending. It has underperformed by 34.74% the S&P500.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others. The company has market cap of $77.04 million. The firm holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. It currently has negative earnings. The Company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons.

More recent Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) news were published by: Seekingalpha.com which released: “Key events next week – healthcare” on May 11, 2018. Also Benzinga.com published the news titled: “22 Stocks Moving In Thursday’s Pre-Market Session” on May 17, 2018. Benzinga.com‘s news article titled: “Earnings Scheduled For May 14, 2018” with publication date: May 14, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: